These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 34274381)

  • 21. miR-140 targeting CTSB signaling suppresses the mesenchymal transition and enhances temozolomide cytotoxicity in glioblastoma multiforme.
    Ho KH; Cheng CH; Chou CM; Chen PH; Liu AJ; Lin CW; Shih CM; Chen KC
    Pharmacol Res; 2019 Sep; 147():104390. PubMed ID: 31398406
    [TBL] [Abstract][Full Text] [Related]  

  • 22. De novo purine biosynthesis is a major driver of chemoresistance in glioblastoma.
    Shireman JM; Atashi F; Lee G; Ali ES; Saathoff MR; Park CH; Savchuk S; Baisiwala S; Miska J; Lesniak MS; James CD; Stupp R; Kumthekar P; Horbinski CM; Ben-Sahra I; Ahmed AU
    Brain; 2021 May; 144(4):1230-1246. PubMed ID: 33855339
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
    Chen Z; Wei X; Shen L; Zhu H; Zheng X
    Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Microarray expression profiles and bioinformatics analysis of mRNAs, lncRNAs, and circRNAs in the secondary temozolomide-resistant glioblastoma.
    Zhao C; Gao Y; Guo R; Li H; Yang B
    Invest New Drugs; 2020 Oct; 38(5):1227-1235. PubMed ID: 31823158
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma.
    Guo G; Sun Y; Hong R; Xiong J; Lu Y; Liu Y; Lu J; Zhang Z; Guo C; Nan Y; Huang Q
    Clin Transl Oncol; 2020 Aug; 22(8):1252-1262. PubMed ID: 31865606
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transcriptional control of O
    Happold C; Stojcheva N; Silginer M; Weiss T; Roth P; Reifenberger G; Weller M
    J Neurochem; 2018 Mar; 144(6):780-790. PubMed ID: 29480969
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.
    Banelli B; Carra E; Barbieri F; Würth R; Parodi F; Pattarozzi A; Carosio R; Forlani A; Allemanni G; Marubbi D; Florio T; Daga A; Romani M
    Cell Cycle; 2015; 14(21):3418-29. PubMed ID: 26566863
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel 3D in vitro model of glioblastoma reveals resistance to temozolomide which was potentiated by hypoxia.
    Musah-Eroje A; Watson S
    J Neurooncol; 2019 Apr; 142(2):231-240. PubMed ID: 30694423
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Loss of programmed cell death 10 activates tumor cells and leads to temozolomide-resistance in glioblastoma.
    Nickel AC; Wan XY; Saban DV; Weng YL; Zhang S; Keyvani K; Sure U; Zhu Y
    J Neurooncol; 2019 Jan; 141(1):31-41. PubMed ID: 30392087
    [TBL] [Abstract][Full Text] [Related]  

  • 30. JNK contributes to temozolomide resistance of stem-like glioblastoma cells via regulation of MGMT expression.
    Okada M; Sato A; Shibuya K; Watanabe E; Seino S; Suzuki S; Seino M; Narita Y; Shibui S; Kayama T; Kitanaka C
    Int J Oncol; 2014 Feb; 44(2):591-9. PubMed ID: 24316756
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemoresistance of glioblastoma cancer stem cells--much more complex than expected.
    Beier D; Schulz JB; Beier CP
    Mol Cancer; 2011 Oct; 10():128. PubMed ID: 21988793
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ID1 Is Critical for Tumorigenesis and Regulates Chemoresistance in Glioblastoma.
    Sachdeva R; Wu M; Smiljanic S; Kaskun O; Ghannad-Zadeh K; Celebre A; Isaev K; Morrissy AS; Guan J; Tong J; Chan J; Wilson TM; Al-Omaishi S; Munoz DG; Dirks PB; Moran MF; Taylor MD; Reimand J; Das S
    Cancer Res; 2019 Aug; 79(16):4057-4071. PubMed ID: 31292163
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Specificity protein 1-modulated superoxide dismutase 2 enhances temozolomide resistance in glioblastoma, which is independent of O
    Chang KY; Hsu TI; Hsu CC; Tsai SY; Liu JJ; Chou SW; Liu MS; Liou JP; Ko CY; Chen KY; Hung JJ; Chang WC; Chuang CK; Kao TJ; Chuang JY
    Redox Biol; 2017 Oct; 13():655-664. PubMed ID: 28822335
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Irradiation or temozolomide chemotherapy enhances anti-CD47 treatment of glioblastoma.
    Gholamin S; Youssef OA; Rafat M; Esparza R; Kahn S; Shahin M; Giaccia AJ; Graves EE; Weissman I; Mitra S; Cheshier SH
    Innate Immun; 2020 Feb; 26(2):130-137. PubMed ID: 31547758
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MicroRNA-132 induces temozolomide resistance and promotes the formation of cancer stem cell phenotypes by targeting tumor suppressor candidate 3 in glioblastoma.
    Cheng ZX; Yin WB; Wang ZY
    Int J Mol Med; 2017 Nov; 40(5):1307-1314. PubMed ID: 28901390
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Combined Treatment with Chemotherapeutic Agents and the Dualsteric Muscarinic Agonist Iper-8-Naphthalimide Affects Drug Resistance in Glioblastoma Stem Cells.
    Guerriero C; Matera C; Del Bufalo D; De Amici M; Conti L; Dallanoce C; Tata AM
    Cells; 2021 Jul; 10(8):. PubMed ID: 34440646
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impairing temozolomide resistance driven by glioma stem-like cells with adjuvant immunotherapy targeting O-acetyl GD2 ganglioside.
    Fleurence J; Bahri M; Fougeray S; Faraj S; Vermeulen S; Pinault E; Geraldo F; Oliver L; Véziers J; Marquet P; Rabé M; Gratas C; Vallette F; Pecqueur C; Paris F; Birklé S
    Int J Cancer; 2020 Jan; 146(2):424-438. PubMed ID: 31241171
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bone marrow response as a potential biomarker of outcomes in glioblastoma patients.
    Vaios EJ; Nahed BV; Muzikansky A; Fathi AT; Dietrich J
    J Neurosurg; 2017 Jul; 127(1):132-138. PubMed ID: 27739940
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long noncoding RNA just proximal to X-inactive specific transcript facilitates aerobic glycolysis and temozolomide chemoresistance by promoting stability of PDK1 mRNA in an m6A-dependent manner in glioblastoma multiforme cells.
    Li XD; Wang MJ; Zheng JL; Wu YH; Wang X; Jiang XB
    Cancer Sci; 2021 Nov; 112(11):4543-4552. PubMed ID: 34390075
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stem cell-associated heterogeneity in Glioblastoma results from intrinsic tumor plasticity shaped by the microenvironment.
    Dirkse A; Golebiewska A; Buder T; Nazarov PV; Muller A; Poovathingal S; Brons NHC; Leite S; Sauvageot N; Sarkisjan D; Seyfrid M; Fritah S; Stieber D; Michelucci A; Hertel F; Herold-Mende C; Azuaje F; Skupin A; Bjerkvig R; Deutsch A; Voss-Böhme A; Niclou SP
    Nat Commun; 2019 Apr; 10(1):1787. PubMed ID: 30992437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.